Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Jamile M. Shammo & Rami S. Komrokji. (2018) Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy. Expert Review of Hematology 11:7, pages 577-586.
Read now
Read now
Drorit G Merkel & Arnon Nagler. (2014) Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes. Expert Review of Anticancer Therapy 14:7, pages 817-829.
Read now
Read now
Mhairi Mitchell, Steven D Gore & Amer M Zeidan. (2013) Iron chelation therapy in myelodysplastic syndromes: where do we stand?. Expert Review of Hematology 6:4, pages 397-410.
Read now
Read now
Katja Sockel, Gerhard Ehninger, Lorenz C Hofbauer & Uwe Platzbecker. (2011) Optimizing management of myelodysplastic syndromes post-allogeneic transplantation. Expert Review of Hematology 4:6, pages 669-680.
Read now
Read now
K. Tolley, N. Oliver, E. Miranda, K. Migliaccio-Walle, D. Bozkaya & Q. Li. (2010) Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients. Journal of Medical Economics 13:3, pages 559-570.
Read now
Read now
Ali Taher & Maria Domenica Cappellini. (2009) Update on the use of deferasirox in the management of iron overload. Therapeutics and Clinical Risk Management 5, pages 857-868.
Read now
Read now
Lisa Chodirker & Richard A Wells. (2009) Iron overload in myelodysplastic syndromes. Expert Review of Hematology 2:3, pages 215-218.
Read now
Read now
Articles from other publishers (40)
Jessica M. Stempel, Nikolai A. Podoltsev & Talib Dosani. (2023) Supportive Care for Patients With Myelodysplastic Syndromes. The Cancer Journal 29:3, pages 168-178.
Crossref
Crossref
Shang-Wei Lin, Chung-Yen Chen, Yu-Chieh Su, Kun-Ta Wu, Po-Chin Yu, Yung-Chieh Yen & Jian-Han Chen. (2022) Mortality Prediction Model before Surgery for Acute Mesenteric Infarction: A Population-Based Study. Journal of Clinical Medicine 11:19, pages 5937.
Crossref
Crossref
Claire Jouzier, Amina Cherait, Pascale Cony‐Makhoul, Jean‐François Hamel, Melanie Veloso, Sylvain Thepot, Thomas Cluzeau, Aspasia Stamatoullas, Alice Garnier, Agnès Guerci‐Bresler, Sophie Dimicoli‐Salazar, Gian Matteo Pica, Stéphane Cheze, Clémence Santana, Fatiha Chermat, Pierre Fenaux & Sophie Park. (2022)
Red blood cell transfusion burden in myelodysplastic syndromes (
MDS
) with ring Sideroblasts (
RS
): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (
GFM
)
. Transfusion 62:5, pages 961-973.
Crossref
Crossref
Shaima Kaka, Ashkan Jahangirnia, Nickolas Beauregard, Alexandra Davis, Alan Tinmouth & Nicolas Chin‐Yee. (2021) Red blood cell transfusion in myelodysplastic syndromes: A systematic review. Transfusion Medicine 32:1, pages 3-23.
Crossref
Crossref
Eléonore Kaphan, David Laurin, Bruno Lafeuillade, Philippe Drillat & Sophie Park. (2020) Impact of transfusion on survival in patients with myelodysplastic syndromes: Current knowledge, new insights and transfusion clinical practice. Blood Reviews 41, pages 100649.
Crossref
Crossref
Ulrich Germing, Ester N. Oliva, Devendra Hiwase & Antonio Almeida. (2019) Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies. HemaSphere 3:6, pages e314.
Crossref
Crossref
P. Joy Ho, Devendra Hiwase, Raj Ramakrishna, Nicholas Viiala, Ann Solterbeck, Robert Traficante, Evren Zor, Othon L. Gervasio, Laura M. High, David M. Ross & Donald K. Bowden. (2019) Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study. HemaSphere 3:3, pages e224.
Crossref
Crossref
Bridget E. Shields, Misha Rosenbach, Zoe Brown-Joel, Anthony P. Berger, Bradley A. Ford & Karolyn A. Wanat. (2019) Angioinvasive fungal infections impacting the skin. Journal of the American Academy of Dermatology 80:4, pages 869-880.e5.
Crossref
Crossref
Heather A. Leitch, Rena Buckstein, Nancy Zhu, Thomas J. Nevill, Karen W.L. Yee, Brian Leber, Mary-Margaret Keating, Eve St. Hilaire, Rajat Kumar, Robert Delage, Michelle Geddes, John M. Storring, April Shamy, Mohamed Elemary & Richard A. Wells. (2018) Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS. Leukemia Research 74, pages 21-41.
Crossref
Crossref
Christopher R. Cogle, Sheila R. Reddy, Eunice Chang, Elya Papoyan, Michael S. Broder, Michael McGuire & Gary Binder. (2017) Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence. Leukemia Research 60, pages 123-128.
Crossref
Crossref
Amer M. Zeidan, Vinod A. Pullarkat & Rami S. Komrokji. (2017) Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome. Critical Reviews in Oncology/Hematology 117, pages 57-66.
Crossref
Crossref
Nicole Carreau, Douglas Tremblay, Michael Savona, Marina Kremyanskaya & John Mascarenhas. (2016) Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes. Blood Reviews 30:5, pages 349-356.
Crossref
Crossref
Stefanie Groepper, Jerome Schlue, Claudia Haferlach & Aristoteles Giagounidis. (2016) Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox. Oncology Research and Treatment 39:6, pages 384-387.
Crossref
Crossref
Ioannis Koutsavlis. (2016) Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes. Anemia 2016, pages 1-7.
Crossref
Crossref
Christopher R. Cogle. (2015) Incidence and Burden of the Myelodysplastic Syndromes. Current Hematologic Malignancy Reports 10:3, pages 272-281.
Crossref
Crossref
Il‐Hwan Kim, Joon‐Ho Moon, Sung‐Nam Lim, Sang‐Kyun Sohn, Hoon‐Gu Kim, Gyeong‐Won Lee, Yang‐Soo Kim, Ho‐Sup Lee, Ki‐Young Kwon, Sung‐Hyun Kim, Kyung‐Tae Park, Joo‐Seop Chung, Won‐Sik Lee, Sang‐Min Lee, Myung‐Soo Hyun, Hawk Kim, Hun‐Mo Ryoo, Sung‐Hwa Bae & Young‐Don Joo. (2015) Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload. Transfusion 55:7, pages 1613-1620.
Crossref
Crossref
Peng Jin, Jinhuan Wang, Xingxin Li, Min Wang, Meili Ge, Jizhou Zhang, Jinbo Huang, Jing Zhang, Zhendong Huang, Neng Nie, Yingqi Shao, Jun Shi & Yizhou Zheng. (2014) Evolution of iron burden in acquired aplastic anemia: a cohort study of more than 3-year follow-up. International Journal of Hematology 101:1, pages 13-22.
Crossref
Crossref
Sally Temraz, Valeria Santini, Khaled Musallam & Ali Taher. (2014) Iron overload and chelation therapy in myelodysplastic syndromes. Critical Reviews in Oncology/Hematology 91:1, pages 64-73.
Crossref
Crossref
Bor-Sheng Ko, Cheng-Shyong Chang, Ming-Chih Chang, Tsai Yun Chen, Tzeon-Jye Chiou, Chang-Fang Chiu, Wen-Li Huang, Woei-Yau Kao, Yii-Jenq Lan, Shen-Fung Lin, Tran-Der Tan, Jih-Luh Tang, Cheng-Hwai Tzeng, Po-Nan Wang, Su-Pen Yet & Hwei-Fang Tien. (2014) Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement. International Journal of Hematology 100:1, pages 7-15.
Crossref
Crossref
Zoe K. McQuilten, Erica M. Wood, Mark N. Polizzotto, Lynda J. Campbell, Meaghan Wall, David J. Curtis, Helen Farrugia, John J. McNeil & Vijaya Sundararajan. (2014) Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study. Cancer 120:11, pages 1686-1694.
Crossref
Crossref
SALVATORE IMPROTA, MARIA ROSARIA VILLA, ANTONIO VOLPE, ANGELA LOMBARDI, PAOLA STIUSO, NICOLA CANTORE & LUCIA MASTRULLO. (2013) Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up. Oncology Letters 6:6, pages 1774-1778.
Crossref
Crossref
Zoe K. McQuilten, Mark N. Polizzotto, Erica M. Wood & Vijaya Sundararajan. (2013) Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008. Transfusion 53:8, pages 1714-1721.
Crossref
Crossref
Heather A. Leitch, Rena Buckstein, April Shamy & John M. Storring. (2013) The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline. Critical Reviews in Oncology/Hematology 85:2, pages 162-192.
Crossref
Crossref
Sung-Eun Lee, Seung-Ah Yahng, Byung-Sik Cho, Ki-Sung Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Hee-Je Kim, Seok-Goo Cho, Dong-Wook Kim, Woo-Sung Min, Chong-Won Park & Jong Wook Lee. (2013) Improvement in Hematopoiesis after Iron Chelation Therapy with Deferasirox in Patients with Aplastic Anemia. Acta Haematologica 129:2, pages 72-77.
Crossref
Crossref
Alan F. ListMaria R. BaerDavid P. SteensmaAzra RazaJason EspositoNoelia Martinez-LopezCarole PaleyJohn FeigertEmmanuel Besa. (2012) Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome. Journal of Clinical Oncology 30:17, pages 2134-2139.
Crossref
Crossref
S. D. Ramsey, J. S. McCune, D. K. Blough, C. L. McDermott, S. J. Beck, J. A. López & H. Joachim Deeg. (2011) Patterns of blood product use among patients with myelodysplastic syndrome. Vox Sanguinis 102:4, pages 331-337.
Crossref
Crossref
Uwe Platzbecker, Lorenz C. Hofbauer, Gerhard Ehninger & Kristina Hölig. (2012) The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leukemia Research 36:5, pages 525-536.
Crossref
Crossref
R. J. Bird, M. Kenealy, C. Forsyth, J. Wellwood, M. F. Leahy, J. F. Seymour & L. B. To. (2012) When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?. Internal Medicine Journal 42:4, pages 450-455.
Crossref
Crossref
Hernani D. Cualing. 2012. Non-Neoplastic Hematopathology and Infections. Non-Neoplastic Hematopathology and Infections
347
373
.
Se Na Moon, Ji Whan Han, Hui Seung Hwang, Mee Jeong Kim, Soon Ju Lee, Jae Young Lee, Chang Kyu Oh & Dae Chul Jeong. (2011) Establishment of Secondary Iron Overloaded Mouse Model: Evaluation of Cardiac Function and Analysis According to Iron Concentration. Pediatric Cardiology 32:7, pages 947-952.
Crossref
Crossref
&NA;. (2011) Use chelation therapy to reduce iron overload and improve survival in patients with myelodysplastic syndromes. Drugs & Therapy Perspectives 27:9, pages 14-17.
Crossref
Crossref
Bin Zhang, Prina Z. Donga, Mitra Corral, Medha Sasane, Jeffrey D. Miller & Chris L. Pashos. (2011) Pharmacoeconomic Considerations in Treating Iron Overload in Patients with β-Thalassaemia, Sickle Cell Disease and Myelodysplastic Syndromes in the US. PharmacoEconomics 29:6, pages 461-474.
Crossref
Crossref
Alberto Fragasso, Angela Ciancio, Clara Mannarella, Carlo Gaudiano, Oronzo Scarciolla, Carlo Ottonello, Marco Francone, Michele Nardella, Angelo Peluso, Angela Melpignano, Maria Rosaria Veglio, Giovanni Quarta & Cristiano Turchetti. (2011) Myocardial iron overload assessed by magnetic resonance imaging (MRI)T2* in multi-transfused patients with thalassemia and acquired anemias. European Journal of Internal Medicine 22:1, pages 62-65.
Crossref
Crossref
Heather A. Leitch. (2011) Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes. Drugs 71:2, pages 155-177.
Crossref
Crossref
Stuart L. GoldbergEr ChenMitra CorralAmy GuoNikita Mody-PatelAndrew L. PecoraMarianne Laouri. (2010) Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries. Journal of Clinical Oncology 28:17, pages 2847-2852.
Crossref
Crossref
R. Donald Harvey. (2010) Myelodysplastic syndromes and the role of iron overload. American Journal of Health-System Pharmacy 67:7_Supplement_2, pages S3-S9.
Crossref
Crossref
Michael Pfeilstöcker. (2010) Iron chelation therapy in myelodysplastic syndromes: evidence-based rationale and comparison of guidelines. memo - Magazine of European Medical Oncology 3:1, pages 11-15.
Crossref
Crossref
Eugene D. Weinberg. (2010) The hazards of iron loading. Metallomics 2:11, pages 732.
Crossref
Crossref
Vinod Pullarkat. (2009) Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?. Blood 114:26, pages 5251-5255.
Crossref
Crossref
Heather A. Leitch & Linda M. Vickars. (2009) Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?. Hematology 2009:1, pages 664-672.
Crossref
Crossref